2024
Vascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchConceptsVascular mimicryBrain metastasesMouse model of metastatic melanomaIncreased risk of metastasisAssociated with tumor volumeMelanoma brain metastasesRisk of metastasisSurvival of miceFuture treatment regimensCell line modelsTumor suppressor pathwayMetastatic melanomaTumor volumeSolid tumorsTreatment regimensTumor typesPoor prognosisHippo tumor suppressor pathwayIncreased riskMouse modelDownstream targets YAPMelanomaMetastasisSuppressor pathwayTumor
2019
PLEKHA5 regulates tumor growth in metastatic melanoma
Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB. PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer 2019, 126: 1016-1030. PMID: 31769872, PMCID: PMC7147081, DOI: 10.1002/cncr.32611.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsApoptosis Regulatory ProteinsBiomarkers, TumorBrain NeoplasmsCell ProliferationFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMaleMelanomaMiceMice, NudeMiddle AgedPhosphatidylinositol 3-KinasesPrognosisProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTumor Cells, CulturedXenograft Model Antitumor AssaysYoung AdultConceptsTumor growthDisseminated melanomaExtracranial melanoma metastasesPI3K/AKT/mTOR pathwayMelanoma brain metastasesBetter overall survivalPI3K/Akt/mTORAKT/mTOR pathwayCell proliferationAkt/mTORMelanoma xenograft modelGrowth of tumorsS cell cycle transitionBrain metastasesOverall survivalPoor prognosisMetastatic melanomaMAPK/ERKSubcutaneous inoculationMelanoma metastasesXenograft modelClinical relevanceMelanoma growthNude miceCerebral specimens
2018
On the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies
Calinescu A, Turcu G, Nedelcu RI, Brinzea A, Hodorogea A, Antohe M, Diaconu C, Bleotu C, Pirici D, Jilaveanu LB, Ion DA, Badarau IA. On the Dual Role of Carcinoembryonic Antigen‐Related Cell Adhesion Molecule 1 (CEACAM1) in Human Malignancies. Journal Of Immunology Research 2018, 2018: 7169081. PMID: 30406153, PMCID: PMC6204181, DOI: 10.1155/2018/7169081.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen-related cell adhesion molecule 1Cell adhesion molecule-1Adhesion molecule-1Molecule-1Role of CEACAM1Progression of malignancyPotential new molecular targetsNew molecular targetsPrognostic factorsSpecific cancer therapyPoor prognosisMetastatic spreadSolid cancersCarcinoembryonic antigenTumor progressionCarcinoembryonic antigen familyHuman malignanciesAntigen familyMolecular targetsCancer therapyBiologic functionsConsiderable downregulationMalignancyTumor suppressorEarly phase
2016
CEACAM1: Expression and Role in Melanocyte Transformation
Turcu G, Nedelcu RI, Ion DA, Brînzea A, Cioplea MD, Jilaveanu LB, Zurac SA. CEACAM1: Expression and Role in Melanocyte Transformation. Disease Markers 2016, 2016: 9406319. PMID: 27642217, PMCID: PMC5013198, DOI: 10.1155/2016/9406319.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigen cell adhesion molecule 1Melanoma patientsCell adhesion molecule-1Standard immunohistochemical panelImmune checkpoint inhibitorsSubgroup of patientsAdhesion molecule-1Development of melanomaAggressive therapyCheckpoint inhibitorsAdvanced melanomaPoor prognosisMetastatic melanomaImmunohistochemical panelCell adhesion moleculeMelanoma treatmentMolecule-1New biomarkersPatientsMelanoma progressionAdhesion moleculesMelanoma cellsMelanomaNormal melanocytesTherapy
2013
Advances in therapy for melanoma brain metastases
Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clinics In Dermatology 2013, 31: 264-281. PMID: 23608446, DOI: 10.1016/j.clindermatol.2012.08.008.Peer-Reviewed Original Research